Literature DB >> 18843023

PTPRJ haplotypes and colorectal cancer risk.

Amanda E Toland1, Laura S Rozek, Shafaq Presswala, Gad Rennert, Stephen B Gruber.   

Abstract

Recent studies from mouse mapping studies for cancer susceptibility have successfully led to the identification of a handful of susceptibility genes. Ptprj was identified as a strong candidate gene for mouse locus susceptibility to colorectal cancer 1, and one variant, rs1566734, showed evidence of preferential allelic imbalance in human colorectal tumors. Haplotypes in human PTPRJ have also been associated with protective effects for breast cancer risk. To determine if variants or haplotype in PTPRJ confer protective or risk effects for colorectal cancer (CRC), we genotyped rs1566734 and six additional PTPRJ haplotype tagging single nucleotide polymorphisms (SNP) in CRC cases and controls from the Molecular Epidemiology of Colorectal Cancer study. There was no evidence for cancer risk with rs1566734 in 1,897 cases and 1,954 controls with a homozygote odds ratio of 1.09 and 95% confidence interval of 0.85 to 1.39. The 6 tagging SNPs resulted in 6 main haplotypes (frequencies, >1%). None of the six tagSNPs individually showed significant evidence for risk; however, rs1503185 showed a nonsignificant protective effect. One haplotype was overrepresented in cases compared with controls, corresponding to a 34% increase in risk CRC, but there was no significant difference overall in haplotype frequencies between cases and controls (global test P statistic=0.19). From this study, we observe no significant increase in risk for human CRC with variants or haplotypes in PTPRJ. Additional studies are warranted to study possible PTPRJ-interacting loci, which are observed with Scc1 in the mouse models for CRC susceptibility.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18843023     DOI: 10.1158/1055-9965.EPI-08-0513

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  6 in total

1.  Comments on: "Meta-analysis of association between Arg326Gln (rs1503185) and Gln276Pro (rs1566734) polymorphisms of PTPRJ gene and cancer risk".

Authors:  Morteza Gholami; Mahsa M Amoli
Journal:  J Appl Genet       Date:  2019-07-12       Impact factor: 3.240

2.  Role of PTPRJ genotype in papillary thyroid carcinoma risk.

Authors:  Rodolfo Iuliano; Dario Palmieri; Huiling He; Angela Iervolino; Eleonora Borbone; Pierlorenzo Pallante; Alessandra Cianflone; Rebecca Nagy; Hansjuerg Alder; George A Calin; Francesco Trapasso; Carla Giordano; Carlo M Croce; Albert de la Chapelle; Alfredo Fusco
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

3.  The effects of CD148 Q276P/R326Q polymorphisms in A431D epidermoid cancer cell proliferation and epidermal growth factor receptor signaling.

Authors:  Lilly He; Keiko Takahashi; Lejla Pasic; Chikage Narui; Philipp Ellinger; Manuel Grundmann; Takamune Takahashi
Journal:  Cancer Rep (Hoboken)       Date:  2021-11-17

4.  iTRAQ plasma proteomics analysis for candidate biomarkers of type 2 incipient diabetic nephropathy.

Authors:  Hongmei Lu; Shaodong Deng; Minghui Zheng; Kunhua Hu
Journal:  Clin Proteomics       Date:  2019-07-31       Impact factor: 3.988

5.  Centenarian Exomes as a Tool for Evaluating the Clinical Relevance of Germline Tumor Suppressor Mutations.

Authors:  Lubomir Balabanski; Dimitar Serbezov; Dragomira Nikolova; Olga Antonova; Desislava Nesheva; Zora Hammoudeh; Radoslava Vazharova; Sena Karachanak-Yankova; Rada Staneva; Marta Mihaylova; Vera Damyanova; Savina Hadjidekova; Draga Toncheva
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

6.  Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.

Authors:  William P D Hendricks; Victoria Zismann; Karthigayini Sivaprakasam; Christophe Legendre; Kelsey Poorman; Waibhav Tembe; Nieves Perdigones; Jeffrey Kiefer; Winnie Liang; Valerie DeLuca; Mitchell Stark; Alison Ruhe; Roe Froman; Nicholas S Duesbery; Megan Washington; Jessica Aldrich; Mark W Neff; Matthew J Huentelman; Nicholas Hayward; Kevin Brown; Douglas Thamm; Gerald Post; Chand Khanna; Barbara Davis; Matthew Breen; Alexander Sekulic; Jeffrey M Trent
Journal:  PLoS Genet       Date:  2018-09-06       Impact factor: 5.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.